MRD: Residual cancer cells undetectable by conventional methods
The clonoSEQ Process
An ultra-sensitive and reproducible method for MRD detection
Clinical studies support the use of the clonoSEQ Process in patients with:
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Mantle Cell Lymphoma
What is MRD ?
MRD is the leading cause of blood cancer relapse
Minimal residual disease (MRD) refers to small numbers of cancer cells that may remain in your body after treatment and eventually cause your disease to come back. There are no signs or symptoms of MRD, and the cells present at such low levels, your doctor may not detect them with routine tests
What is MRD testing used for?
More sensitive MRD detection may allow earlier intervention
The clonoSEQ MRD Test can detect disease at levels as low as 1 cancer cell per 1 million total white blood cells (WBC). This is up to 100 times more sensitive than other methods used to detect MRD
per million wbc